Talus Bio

talus.bio →

-81%

est. 2Y upside i

HealthcareSeed

Discovering drugs that target the DNA regulome

Rank

#1625

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Medium

Talus Bio presents a high-risk, high-reward equity opportunity.

Last updated: March 10, 2026

Bull (25%)+300%

Talus Bio's MARMOT platform successfully advances multiple preclinical programs into the clinic, particularly for Brachyury-driven cancers and prostate cancer, leading to a significant Series B/C round or an early acquisition by a major pharmaceutical company at a valuation of $120M-$150M.

Base (35%)+50%

Talus Bio continues to make steady preclinical progress, validating its MARMOT platform and securing additional non-dilutive funding and a modest Series B round. The company maintains its niche in undruggable transcription factors, reaching a valuation of $45M-$55M through continued platform development and early-stage pipeline advancement.

Bear (40%)-80%

Talus Bio faces challenges in translating its platform to clinical candidates, or encounters unforeseen technical hurdles. Intense competition from other AI drug discovery firms or a failure to secure sufficient follow-on funding leads to a down round or a low-value acquisition, resulting in a valuation of $5M-$10M, significantly impacting common stock value due to liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

87%

Investors hold $27M in liquidation preferences ahead of common stock on a $31M valuation, meaning common shareholders get little to nothing in an exit at or below current valuation.

Dilution Risk

high

As a Seed+ stage company, significant future funding rounds (Series A, B, C, etc.) are expected, leading to substantial dilution for current equity holders.

Secondary Liquidity

limited

Accredited investors may be able to purchase shares on the secondary market through platforms like Premier Alternatives, offering some limited liquidity options.

Questions to Ask at the Interview

Strategic questions based on Talus Bio's data — designed to show you've done your homework.

  • 1

    “How does Talus Bio plan to differentiate its MARMOT platform and pipeline from direct competitors like Arpeggio Bio, especially as more companies enter the AI-driven transcription factor space?”

  • 2

    “Given the preclinical stage and high capital intensity of drug development, what are the key milestones Talus Bio aims to achieve in the next 18-24 months to de-risk its programs and attract future funding rounds?”

  • 3

    “With a significant preference stack from prior funding, how does Talus Bio envision creating substantial value for common stock holders, and what is the anticipated timeline for a liquidity event (IPO or acquisition)?”

Community

Valuation Sentiment

Our model estimates -81% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.